CUTIA-B(02487): CU-40102 (topical finasteride spray) receives marketing approval from the Pharmaceutical Administration Bureau of Macau

CUTIA-B(02487) announces that the Group's CU-40102 (topical finasteride spray) has received marketing approval from the Pharmaceutical Administration Bureau of the Macao Special Administrative Region Government of China. The approved indication is for the treatment of androgenetic alopecia. This is another major milestone for CU-40102 following its marketing approvals from China's National Medical Products Administration and the Department of Health of the Hong Kong Special Administrative Region Government of China. Finasteride, as a specific competitive inhibitor of type II 5-reductase, inhibits the conversion of testosterone to dihydrotestosterone in the scalp and can treat androgenetic alopecia. Unlike oral finasteride, CU-40102's topical formulation allows patients to apply the medication directly and precisely to the scalp surface. Compared with oral medication, it can reduce systemic exposure to the drug. The Group believes that CU-40102 as a topical medication will be more easily accepted by patients, providing an alternative solution for patients with androgenetic alopecia and becoming a new medication option for patients. As an important product of the Group that has obtained marketing approval in the field of hair diseases and care, CU-40102 is undergoing extensive commercialization in China. This approval will further deepen CU-40102's international layout, broaden CU-40102's market space, and benefit more patients with androgenetic alopecia.